Antihypertensives × cardiovascular events

TrialThe New England journal of medicine2016

Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease.

Salim Yusuf et al.PubMed ↗Publisher ↗

  • Combined-therapy group (rosuvastatin and the two antihypertensive agents)looks good hereLower first coprimary outcome, lower second coprimary outcome.Randomised, large.

What the trial testedrandomised · 12,705 people · 2016

Randomised vs dual-placebo group

Lowered first coprimary outcome

−29%−44% to −10%

combined-therapy group (rosuvastatin and the two antihypertensive agents) vs dual-placebo group

4 in 100 instead of 5

Bigger than 7 in 10 for cardiovascular events

As reported

HR 0.71, 95% CI 0.56–0.90

Randomised vs dual-placebo group

Lowered second coprimary outcome

−28%−43% to −11%

combined-therapy group (rosuvastatin and the two antihypertensive agents) vs dual-placebo group

4 in 100 instead of 5

Bigger than 7 in 10 for cardiovascular events

As reported

HR 0.72, 95% CI 0.57–0.89

+2 more in the walkthrough ↓

Who was studied, and how

12,705people with hypertension, in this paper

The trial randomly assignedassigned by chance

combined-therapy group (rosuvastatin and the two antihypertensive agents)
dual-placebo group

Lowered first coprimary outcome−29%

Lowered second coprimary outcome−28%

Reported lower the LDL cholesterol level, no range given−33.7

randomised

the abstract, start to end

in the LDL cholesterol level was 33.7 mg per deciliter (0.87 mmol per liter) greater in the combined-therapy group than in the dual-placebo group, and the decrease in systolic blood pressure was 6.2 mm Hg greater with combined

in the dual-placebo group (hazard ratio, 0.71; 95% confidence interval [CI],

(5.9%), respectively (hazard ratio, 0.72; 95% CI, 0.57 to 0.89;

← favours treatmentfavours comparator →
could be chance
No interval given · direction only, strength unknown
Decrease in the LDL cholesterol levelcombined-therapy group (rosuvastatin and the two antihypertensive agents) vs dual-placebo group
−33.7
Decrease in systolic blood pressurecombined-therapy group (rosuvastatin and the two antihypertensive agents) vs dual-placebo group
−6.20
First coprimary outcome (composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke)combined-therapy group (rosuvastatin and the two antihypertensive agents) vs dual-placebo group
HR 0.710.56–0.90
Second coprimary outcome (first coprimary outcome additionally included heart failure, cardiac arrest, or revascularization)combined-therapy group (rosuvastatin and the two antihypertensive agents) vs dual-placebo group
HR 0.720.57–0.89
StatinsAntihypertensivesLipidsBlood pressureCardiovascular events

Antihypertensives × cardiovascular eventshelps?one trial

unlikelylikely
0.50only evidence

Statins × cardiovascular eventshelps?replicated

unlikelylikely
0.860.85 without it
← favours treatmentfavours comparator →
this papermore certainless certain
1 / 7

130 papers cite itlatest 60 shown

2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
this paperpooled ittrialcites it

3 trials

Full record →Abstract, authors, funding and every citing paper · PMID 27039945